Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2025-11-05 Regulatory Filings
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-11-05 English
6-K
Regulatory Filings
2025-11-05 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
Transaction in Own Shares Classification · 95% confidence The document contains two distinct announcements: one regarding a CEO transition (Management change) and one regarding a synthetic share repurchase (Capital/Financing update). Since the document is an 'Ad hoc Announcement' under the Market Abuse Regulation covering multiple corporate actions, and given the primary focus on the capital structure change (synthetic share repurchase) and management transition, it fits best under the 'Regulatory Filings' (RNS) category as it serves as a general regulatory disclosure for material events.
2025-11-05 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
Earnings Release Classification · 100% confidence The document is a comprehensive quarterly financial results announcement for QIAGEN N.V. for Q3 2025. It details net sales, EPS, operating income, segment performance, and future outlooks. While it contains management commentary, it is primarily an initial announcement of quarterly financial results (Earnings Release). It is not a full 10-K (annual report) or a transcript of a call, but rather the press release summarizing the key financial highlights for the period. Q3 2025
2025-11-05 English
QIAGEN N.V.: QIAGEN announces CEO transition plan
Board/Management Information Classification · 100% confidence The document is an official announcement regarding a CEO transition plan at QIAGEN N.V. It explicitly mentions the departure of the current CEO and the initiation of a search for a successor. This falls under the category of changes in senior management, which is classified as MANG (Board/Management Information).
2025-11-04 English
Qiagen N.V., Halfjaarlijkse financiële verslaggeving
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Financial Report' for the period ended June 30, 2025. It contains comprehensive condensed consolidated financial statements (balance sheets, income statements, cash flows, etc.) and explanatory notes. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-30 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.